Unlocking Lupus Diagnosis: Understanding the 11 Criteria for Accurate Identification

Systemic lupus erythematosus (SLE), often simply called lupus, is a chronic autoimmune disease that can affect nearly any organ system in the body. Diagnosing SLE can be a complex process because its symptoms are wide-ranging and can mimic those of other conditions. For healthcare professionals, understanding the criteria for lupus diagnosis is crucial for early and accurate identification, leading to timely management and improved patient outcomes. This comprehensive guide delves into the diagnostic criteria for SLE, providing an in-depth look at the 11 criteria initially established by the American College of Rheumatology (ACR) and how these have evolved with newer classification systems.

I. The Foundation: 1982 and 1997 ACR Criteria for SLE

The American College of Rheumatology first established criteria for the classification of SLE in 1971, later revising them in 1982 and again in 1997. The 1997 ACR criteria, often referred to as the 11 Criteria For Lupus Diagnosis, became a widely used benchmark for classifying SLE in clinical practice and research.

A patient is classified as having SLE if they meet at least 4 out of these 11 criteria, either simultaneously or serially during the course of their illness. These criteria encompass a range of clinical and immunological manifestations:

1. Malar Rash: This is a classic SLE symptom, often described as a “butterfly rash”. It’s an erythematous (reddened) rash across the cheeks and bridge of the nose, typically sparing the nasolabial folds (the creases between the nose and mouth). The rash can be flat or raised and is often photosensitive, meaning it worsens with sun exposure.

2. Discoid Rash: Discoid lupus is a chronic skin condition characterized by raised, scaly, coin-shaped (discoid) lesions. These lesions can be erythematous or hyperpigmented and often cause scarring, especially on the face, scalp, and ears.

3. Photosensitivity: This refers to an abnormal skin reaction to sunlight or ultraviolet (UV) light. Patients may develop a skin rash or worsening of their SLE symptoms after sun exposure. Photosensitivity is a common feature of various lupus subtypes.

4. Oral or Nasal Ulcers: Mouth or nose ulcers in SLE are typically painless, although they can sometimes be uncomfortable. These ulcers can occur on the mucous membranes of the mouth (oral ulcers) or nose (nasal ulcers). Recurrent oral ulcers are more common in SLE than nasal ulcers.

5. Arthritis: Lupus arthritis is characterized by non-erosive inflammation of the joints. It typically affects small joints in the hands, wrists, and knees, but can involve any joint. The arthritis is usually symmetrical (affecting joints on both sides of the body) and can cause pain, swelling, tenderness, and stiffness.

6. Serositis: This criterion refers to inflammation of the serous membranes, which are linings surrounding organs in the chest and abdomen. In SLE, serositis commonly manifests as pleuritis (inflammation of the lining of the lungs) or pericarditis (inflammation of the lining of the heart). Pleuritis causes chest pain that worsens with breathing, while pericarditis can cause chest pain and other cardiac symptoms.

7. Renal Disorder: Lupus nephritis, or kidney involvement in SLE, is a serious complication. The renal disorder criterion is met if there is persistent proteinuria (excess protein in the urine, greater than 500 mg per day) or cellular casts (abnormal formations in the urine, including red blood cell, granular, tubular, or mixed casts). Lupus nephritis can range from mild to severe and can lead to kidney failure if untreated.

8. Neurologic Disorder: SLE can affect the central nervous system (CNS), leading to various neurological manifestations. The neurologic disorder criterion includes seizures or psychosis in the absence of other known causes. Neuropsychiatric lupus can present with a wide array of symptoms, making diagnosis challenging.

9. Hematologic Disorder: SLE can cause abnormalities in blood cell counts. The hematologic disorder criterion includes:

   • Hemolytic anemia: Anemia caused by the destruction of red blood cells.
   • Leukopenia: Low white blood cell count (less than 4000/mm3).
   • Lymphopenia: Low lymphocyte count (less than 1500/mm3).
   • Thrombocytopenia: Low platelet count (less than 100,000/mm3).
     These hematologic abnormalities must be present on two or more occasions to meet the criterion and should not be due to medications known to cause these conditions.

10. Immunologic Disorder: This criterion is based on the presence of specific autoantibodies, which are antibodies that mistakenly target the body’s own tissues. The immunologic disorder criterion includes:

    • Anti-dsDNA antibody: Antibody to double-stranded DNA.
    • Anti-Sm antibody: Antibody to Smith nuclear antigen.
    • Antiphospholipid antibodies: Including lupus anticoagulant, anticardiolipin antibodies (IgG or IgM), or anti-β2 glycoprotein I antibodies.
    • False-positive serological test for syphilis: Specifically, a false-positive VDRL or RPR test.

11. Antinuclear Antibody (ANA): A positive ANA test is a hallmark of SLE and other autoimmune diseases. The ANA criterion requires a positive ANA test in the absence of drugs known to induce drug-induced lupus. While highly sensitive for SLE, ANA is not specific, as it can be positive in other conditions and even in some healthy individuals.

II. Evolution of Lupus Diagnostic Criteria: SLICC and EULAR/ACR

While the 1997 ACR criteria were valuable, they had limitations in sensitivity, particularly in identifying patients with early or milder forms of SLE. This led to the development of newer classification criteria, including the Systemic Lupus International Collaborating Clinics (SLICC) criteria in 2012 and the European League Against Rheumatism (EULAR)/ACR criteria in 2019.

1. 2012 SLICC Criteria: Enhancing Sensitivity and Clinical Relevance

The SLICC criteria aimed to improve upon the ACR criteria by increasing sensitivity and incorporating a broader range of clinical and immunological features. The SLICC criteria require either:

• Meeting at least 4 criteria, with at least one clinical and one immunological criterion.
• Biopsy-proven lupus nephritis in the presence of ANA or anti-dsDNA antibodies.

The SLICC criteria expanded upon the ACR criteria by:

• Adding new clinical criteria: Including acute cutaneous lupus erythematosus (ACLE), subacute cutaneous lupus erythematosus (SCLE), alopecia, Raynaud’s phenomenon, hemolytic anemia, thrombocytopenia, and cellular casts (as a separate clinical criterion from proteinuria).
• Expanding immunological criteria: Including low complement (C3, C4, CH50), direct Coombs’ test in the absence of hemolytic anemia, and anti-Ro (SSA) or anti-La (SSB) antibodies.
• Removing alopecia and Raynaud’s phenomenon from the 1997 ACR criteria list but reintroducing them as SLICC clinical criteria.

2. 2019 EULAR/ACR Criteria: A Weighted Scoring System

The 2019 EULAR/ACR criteria represent a significant shift towards a weighted scoring system for SLE classification. This system assigns points to various clinical and immunological criteria, with a total score of 10 or more points and at least one clinical criterion being required for SLE classification.

The EULAR/ACR criteria include:

Entry Criterion:

• ANA at or above the laboratory reference range. This is an entry criterion, meaning a positive ANA is required before proceeding to scoring.

Clinical Domains and Criteria (with Points):

• Constitutional (2 points): Fever, fatigue.
• Cutaneous (2-10 points): Non-scarring alopecia (2), oral ulcers (2), subacute cutaneous or discoid lupus (4), acute cutaneous lupus (6).
• Arthritis (4-6 points): Synovitis of ≥2 joints (4), synovitis of small joints and large joints (6).
• Neuropsychiatric (2-8 points): Delirium (2), psychosis (3), seizures (5), myelitis (6), peripheral neuropathy (8).
• Serositis (6 points): Pleural or pericardial effusion, acute pericarditis.
• Renal (4-10 points): Proteinuria >0.5g/24 hours or urine protein/creatinine ratio >0.5g/g (4), lupus nephritis class II or V (8), lupus nephritis class III or IV (10).
• Hematologic (3-4 points): Leukopenia (<4000/µL) (3), thrombocytopenia (<100,000/µL) (4), autoimmune hemolysis (4).

Immunological Domains and Criteria (with Points):

• Antiphospholipid antibodies (2 points): Lupus anticoagulant, anticardiolipin antibodies, anti-β2 glycoprotein I antibodies.
• Complement proteins (3-4 points): Low C3 or C4 (3), low C3 and C4 (4).
• Highly specific antibodies (6 points): Anti-dsDNA, anti-Sm.

This point system allows for a more nuanced assessment of SLE and may capture a broader spectrum of patients compared to the earlier criteria sets.

III. Clinical Application and Considerations

It is crucial to remember that classification criteria are primarily designed for research purposes and to standardize patient populations in clinical studies. While they are helpful in clinical practice, they are not intended to be rigid diagnostic rules.

Diagnosis of SLE remains a clinical judgment based on a comprehensive evaluation, including:

• Detailed patient history: Gathering information about symptoms, onset, duration, and relevant medical history.
• Thorough physical examination: Assessing for clinical manifestations related to SLE criteria.
• Laboratory investigations: Including ANA, specific autoantibody testing, complete blood count, renal function tests, complement levels, and inflammatory markers.
• Imaging and histopathology: When indicated, such as renal biopsy for suspected lupus nephritis or skin biopsy for cutaneous lupus.

Key considerations in applying lupus diagnostic criteria:

• Criteria are not always present at initial presentation: SLE can evolve over time, and patients may not meet the criteria early in the disease course. Serial assessments and monitoring are important.
• Differential diagnosis: It is essential to rule out other conditions that can mimic SLE, such as other autoimmune diseases, infections, and malignancies.
• Clinical expertise: Interpreting criteria and integrating them with clinical findings requires expertise in rheumatology.
• No single criterion is definitive: The diagnosis of SLE is based on the constellation of findings rather than any single positive test or symptom.
• ANA negativity in SLE: While rare, ANA-negative lupus exists, particularly in patients with specific autoantibodies like anti-Ro (SSA). In such cases, clinical suspicion and other diagnostic findings are critical.

IV. Conclusion: Towards Earlier and More Accurate Lupus Diagnosis

Understanding the 11 criteria for lupus diagnosis, as initially defined by the ACR, and the evolution of these criteria through the SLICC and EULAR/ACR systems is essential for healthcare professionals. These criteria provide a framework for recognizing and classifying SLE, aiding in research and clinical practice.

However, it is paramount to remember that diagnosing SLE is a complex clinical process that goes beyond simply counting criteria. A holistic approach, integrating clinical judgment, patient history, physical examination, and appropriate investigations, is crucial for achieving earlier and more accurate lupus diagnosis. This ultimately leads to timely intervention, personalized management strategies, and improved outcomes for individuals living with SLE.

By staying informed about the evolving landscape of lupus diagnostic criteria and focusing on comprehensive patient evaluation, clinicians can enhance their ability to identify and manage this challenging autoimmune disease effectively.

References

1. Molina-Rios S, Rojas-Martinez R, Estévez-Ramirez GM, Medina YF. Systemic lupus erythematosus and antiphospholipid syndrome after COVID-19 vaccination. A case report. Mod Rheumatol Case Rep. 2023 Jan 03;7(1):43-46.
2. Selvaraja M, Too CL, Tan LK, Koay BT, Abdullah M, Shah AM, Arip M, Amin-Nordin S. Human leucocyte antigens profiling in Malay female patients with systemic lupus erythematosus: are we the same or different? Lupus Sci Med. 2022 Feb;9(1)
3. Losada-García A, Cortés-Ramírez SA, Cruz-Burgos M, Morales-Pacheco M, Cruz-Hernández CD, Gonzalez-Covarrubias V, Perez-Plascencia C, Cerbón MA, Rodríguez-Dorantes M. Hormone-Related Cancer and Autoimmune Diseases: A Complex Interplay to be Discovered. Front Genet. 2021;12:673180.
4. Tayem MG, Shahin L, Shook J, Kesselman MM. A Review of Cardiac Manifestations in Patients With Systemic Lupus Erythematosus and Antiphospholipid Syndrome With Focus on Endocarditis. Cureus. 2022 Jan;14(1):e21698.
5. Tsai HL, Chang JW, Lu JH, Liu CS. Epidemiology and risk factors associated with avascular necrosis in patients with autoimmune diseases: a nationwide study. Korean J Intern Med. 2022 Jul;37(4):864-876.
6. Scheen M, Adedjouma A, Esteve E, Buob D, Abisror N, Planche V, Fain O, Boffa JJ, De Seigneux S, Mekinian A, Haidar F. Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management. Autoimmun Rev. 2022 May;21(5):103072.
7. Takeshima Y, Iwasaki Y, Nakano M, Narushima Y, Ota M, Nagafuchi Y, Sumitomo S, Okamura T, Elkon K, Ishigaki K, Suzuki A, Kochi Y, Yamamoto K, Fujio K. Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus. Ann Rheum Dis. 2022 Jun;81(6):845-853.
8. Hsu T, Nguyen P, Petronic-Rosic V. A case of systemic lupus erythematosus with cutaneous granulomatous vasculitis. JAAD Case Rep. 2022 Mar;21:93-96.
9. Sinha A, Rivera AS, Chadha SA, Prasada S, Pawlowski AE, Thorp E, DeBerge M, Ramsey-Goldman R, Lee YC, Achenbach CJ, Lloyd-Jones DM, Feinstein MJ. Comparative Risk of Incident Coronary Heart Disease Across Chronic Inflammatory Diseases. Front Cardiovasc Med. 2021;8:757738.
10. Liu T, Neuner R, Thompson A, Pottackal G, Petullo D, Liu J, Nikolov N, Sahajwalla C, Doddapaneni S, Chen J. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective. Lupus. 2022 Apr;31(4):424-432.
11. Kanderi T, Kim J, Chan Gomez J, Joseph M, Bhandari B. Warm Autoimmune Hemolytic Anemia as the Initial Presentation of Systemic Lupus Erythematosus (SLE): A Case Report. Am J Case Rep. 2021 Dec 12;22:e932965.
12. Emorinken A, Dic-Ijiewere MO, Erameh CO, Ugheoke AJ, Agbadaola OR, Agbebaku FO. Clinical and laboratory profile of systemic lupus erythematosus patients at a rural tertiary centre in South-South Nigeria: experience from a new rheumatology clinic. Reumatologia. 2021;59(6):402-410.
13. Mukkera S, Mannem M, Chamarti K, Pillarisetty L, Vulasala SS, Alahari L, Ammu A, Mukkera A, Vadlapatla RK. Systemic Lupus Erythematosus-Associated Serositis Managed With Intravenous Belimumab: A Case Report. Cureus. 2022 Feb;14(2):e22639.
14. Ruacho G, Lira-Junior R, Gunnarsson I, Svenungsson E, Boström EA. Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus. Lupus Sci Med. 2022 Mar;9(1)
15. Cavalli S, Lonati PA, Gerosa M, Caporali R, Cimaz R, Chighizola CB. Beyond Systemic Lupus Erythematosus and Anti-Phospholipid Syndrome: The Relevance of Complement From Pathogenesis to Pregnancy Outcome in Other Systemic Rheumatologic Diseases. Front Pharmacol. 2022;13:841785.
16. Aringer M, Costenbader K, Johnson SR. Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus. Expert Rev Clin Immunol. 2022 Feb;18(2):135-144.
17. Sternhagen E, Bettendorf B, Lenert A, Lenert PS. The Role of Clinical Features and Serum Biomarkers in Identifying Patients with Incomplete Lupus Erythematosus at Higher Risk of Transitioning to Systemic Lupus Erythematosus: Current Perspectives. J Inflamm Res. 2022;15:1133-1145.
18. Tektonidou MG. Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis. J Autoimmun. 2022 Apr;128:102813.
19. Takenaka K, Tsukamoto H, Otsuka T, Yoshimatsu H, Nagasawa K, Niho Y. [A case of systemic lupus erythematosus who developed nodular shadows in the lung in parallel with the disease activity]. Ryumachi. 1993 Aug;33(4):325-9.
20. Skudalski L, Shahriari N, Torre K, Santiago S, Bibb L, Kodomudi V, Grant-Kels JM, Lu J. Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sjögren syndrome. J Am Acad Dermatol. 2022 Jul;87(1):1-18.
21. Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X211073001.
22. Wafa A, Hicham H, Naoufal R, Hajar K, Rachid R, Souad B, Mouna M, Zoubida MT, Mohamed A. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 20 Moroccan adult patients. Clin Rheumatol. 2022 Jul;41(7):2021-2033.
23. Sahoo RR, Wakhlu A, Agarwal V. Neglected tropical rheumatic diseases. Clin Rheumatol. 2022 May;41(5):1293-1304.
24. Kayser C, Dutra LA, Dos Reis-Neto ET, Castro CHM, Fritzler MJ, Andrade LEC. The Role of Autoantibody Testing in Modern Personalized Medicine. Clin Rev Allergy Immunol. 2022 Oct;63(2):251-288.